Abstract:The high prevalence of hypertension in China is well known, with stroke being the most common cause of death and disability. 1 GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117-171 Summary Full Text Full Text PDF PubMed Scopus (5370) Google Scholar Two large nationwide studies reported in The Lancet2 Lu J Lu Y Wang X et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017; (published online Oct 25.)http://dx.doi.org/10.1016/S0140-6736(17)32478-9 Summary Full Text Full Text PDF Scopus (567) Google Scholar , 3 Su M Zhang Q Bai X et al. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet. 2017; (published online Oct 25.)http://dx.doi.org/10.1016/S0140-6736(17)32476-5 Summary Full Text Full Text PDF Scopus (82) Google Scholar highlight that although the prevalence of hypertension in China is similar to that suggested in previous studies, it is simple deficiencies in the country's health system that make a large contribution to the disease burden. Both studies used data from the PEACE (Patient-Centred Evaluative Assessment of Cardiac Events) Million Persons Project (MPP), which enrolled 1·7 million adults aged 35–75 years from across China. This is a population-centred, national screening initiative to detect populations at high risk of cardiovascular disease. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)Among Chinese adults aged 35–75 years, nearly half have hypertension, fewer than a third are being treated, and fewer than one in twelve are in control of their blood pressure. The low number of people in control is ubiquitous in all subgroups of the Chinese population and warrants broad-based, global strategy, such as greater efforts in prevention, as well as better screening and more effective and affordable treatment. Full-Text PDF Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional surveyChina has marked deficiencies in the availability, cost, and prescription of antihypertensive medications. High-value medications are not preferentially used. Future efforts to reduce the burden of hypertension, particularly through the work of primary health-care providers, will need to improve access to, and use of, antihypertensive medications, paying particular attention to those with high value. Full-Text PDF

Appropriateness of the 2017 ACC/AHA Guidelines: Applied to Data from the China National Stroke Screening and Prevention Project Study

The Rates and the Determinants of Hypertension According to the 2017 Definition of Hypertension by ACC/AHA and 2014 Evidence-Based Guidelines Among Population Aged ≥40 Years Old

Prevalence and Treatment of Hypertension in China: Impacts of 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline.

Hypertension Subtypes, Mortality Risk, and Differential Effects Between Two Hypertension Guidelines

Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study

Association Of General And Central Adiposity With Blood Pressure Among Chinese Adults: Results From The China National Stroke Prevention Project

The Association of Blood Pressure Defined by the 2017 ACC/AHA Guidelines and Cardiovascular Disease Risk for Middle-Aged and Elderly People in China: A Cohort Study

Hypertension in China: the Gap Between Policy and Practice

Similarities in Hypertension Status but Differences in Mortality Risk: A Comparison of 2017 ACC/AHA and 2018 Chinese Hypertension Guidelines

Blood pressure categories defined by the 2017 ACC/AHA guideline and all-cause mortality: a national cohort study in China and meta-analysis

Increased Risk of Hypertension in Young Adults in Southwest China: Impact of the 2017 ACC/AHA High Blood Pressure Guideline

Hypertension Defined by 2017 ACC/AHA Guideline, Ideal Cardiovascular Health Metrics, and Risk of Cardiovascular Disease: A Nationwide Prospective Cohort Study

Abstract P205: Potential Impact of the 2014 High Blood Pressure Guideline on Adults in China and the US

Comparative Analysis of Hypertension Guidelines: Unveiling Consensus and Discrepancies in Lifestyle Modifications for Blood Pressure Control

Potential epidemiological impact of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline on the Chinese population: a cross-sectional study in rural areas of Liaoning Province

Association Between Blood Pressure Levels and Cardiovascular Deaths: a 20-Year Follow-Up Study in Rural China

Social determinants of health, blood pressure classification, and incident stroke in community-dwelling adults: a prospective cohort study

The Association of Stage 1 Hypertension Defined by the 2017 ACC/AHA Guideline with Stroke and Its Subtypes among Elderly Chinese

Associations of Blood Pressure Categories According to the 2017 American College of Cardiology/American Heart Association Hypertension Guideline and Long-Term Blood Pressure Change with Incident Cardiovascular Disease in Middle-Aged and Elderly Chinese: the Dongfeng-Tongji Cohort Study

Comprehensive Treatment of Hypertension Middle-Aged and Elderly People: Cross-Sectional Survey Data from the China Health and Retirement Longitudinal Study (CHARLS)

Factors associated with awareness, treatment and control of hypertension among 3579 hypertensive adults in China: data from the China Health and Nutrition Survey